Loading...
Market
What will be the global market size of dual GLP-1/GIP receptor agonists by 2026?
4
Resolution / Starting Odds
Less than $1 billion • 25%
$1 billion to $5 billion • 25%
$5 billion to $10 billion • 25%
More than $10 billion • 25%
Market research reports, industry analysis
Story
Roche's CT-388 Shows 18.8% Weight Loss in Phase I Trial at 24 Weeks
May 16, 2024, 06:25 AM
Roche has reported positive Phase I results for its dual GLP-1/GIP receptor agonist, CT-388, in people with obesity. The drug demonstrated an 18.8% placebo-adjusted weight loss at 24 weeks, which is faster than the results seen with Wegovy. This promising data comes from a trial size of 96 participants and is part of Roche's $3.1 billion acquisition of Carmot Therapeutics. The news has already impacted Roche's shares positively, with shares trading up.
View original story
Similar markets
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
No competitive drugs launched • 25%
1-2 competitive drugs launched • 25%
3-5 competitive drugs launched • 25%
More than 5 competitive drugs launched • 25%
Increase by over 50% • 25%
Increase by 20-50% • 25%
Increase by less than 20% • 25%
Decrease • 25%
Less than 10 countries • 25%
10-20 countries • 25%
20-30 countries • 25%
More than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
Under 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Over 75% • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%